Moderna Advances Phase 3 H5 Bird Flu Shot, Expanding Its Pandemic Vaccine Pipeline
Moderna (MRNA) announced an update on their ongoing clinical study.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Moderna (MRNA) is advancing a large Phase 3 study called “A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults.” The goal is to see how well its new H5 bird flu shot triggers an immune response after two doses and to track safety in adults 18 and older, a key step toward a future pandemic-ready flu product.
The main treatment is mRNA-1018-H5, an mRNA-based vaccine given as a muscle shot. It is designed to train the body to recognize and fight H5 influenza strains, while a matched placebo shot is used as a control to measure true vaccine effects.
The trial is interventional and randomized, so people are assigned by chance to vaccine or placebo groups. It uses a parallel design with triple blinding, meaning participants, trial staff, and outcome assessors do not know who gets the real shot, and the core aim is to prevent flu rather than treat existing illness.
The study began recruiting on March 22, 2026, marking the formal start of data collection. The most recent update was posted on April 2, 2026, signaling that the protocol and recruitment details are current and giving investors confidence that execution is on track.
This update supports the view that Moderna is pushing hard into pandemic flu, adding another late-stage asset beyond its Covid franchise. Success here could support MRNA’s valuation, improve sentiment around its broader vaccine platform, and intensify competition for legacy flu players like GSK and Sanofi, though near-term revenue impact remains several years away.
The trial is still recruiting and active, and further details on progress and design are available on the ClinicalTrials portal.
To learn more about MRNA’s potential, visit the Moderna drug pipeline page.
